Remdesivir-related low heart rate reported in elderly COVID-19 patient
A 78-year-old COVID-19 patient experienced significant bradycardia after beginning treatment with remdesivir, according to a new analysis published in Heart Rhythm Case Reports.
Although the patient’s symptoms did resolve within a few days, the report’s authors emphasized that it remains important to track any and all adverse effects associated with treatments for COVID-19.
“Remdesivir has become the standard of care for COVID-19 pneumonia, and there is a paucity of data on its cardiac effects,” lead author Jomel Patrick Jacinto, DO, a resident at Regional Medical Center Bayonet Point in Hudson, Florida, said in a statement. “While it is known to be well tolerated and effective, it’s critical to note its potential adverse effects on the cardiovascular system. To our knowledge, this is the first reported case of remdesivir-induced hemodynamically unstable sinus bradycardia.”
The patient was in respiratory distress when she first arrived at the hospital, the report’s authors explained. After it was confirmed that she had COVID-19, the team began antiviral therapy with remdesivir. Approximately 20 hours later, her heart rate dropped to 38 beats per minute. An electrocardiogram was ordered, and it revealed that the patient had sinus bradycardia.
The team started a dopamine drip, and the patient began to improve. The planned five-day remdesivir treatment course was successfully completed.
“Most hospitals have the ability to support the patient through the five-day treatment course to completion, using medications such as dopamine to nullify severe bradycardia,” Jacinto said in the same statement. “Having a heightened awareness of its cardiac safety profile is essential to make effective clinical decisions in treatment of patients with remdesivir.”
Read the full report here.
Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.